Phenylephrine is a synthetic sympathomimetic that differs from epinephrine and norepinephrine in one pharmacologically defining way: it is a selective alpha-1 (α1) agonist with negligible beta-adrenergic activity at therapeutic doses. This selectivity makes it pharmacologically predictable but also mechanistically one-dimensional, providing vasoconstriction and blood pressure support without the cardiac stimulation or bronchodilation of the mixed-receptor catecholamines.
Mechanism. Phenylephrine is a direct-acting α1 agonist that activates the Gq/phospholipase C-beta (PLC-β)/inositol trisphosphate (IP3)/calcium pathway in vascular smooth muscle, producing arteriolar and venous vasoconstriction and increasing systemic vascular resistance (SVR). At standard clinical doses it has no meaningful agonist activity at β1, β2, or α2 receptors, and no dopaminergic activity. Because it lacks β1 stimulation, it does not increase heart rate or myocardial contractility directly. Instead, the rise in arterial pressure from α1-mediated vasoconstriction activates baroreceptors, triggering a compensatory reflex bradycardia via increased vagal tone. This reflex bradycardia is a defining characteristic of phenylephrine and distinguishes it clinically from norepinephrine, which also raises pressure but whose concomitant β1 stimulation partially offsets the baroreceptor response. The absence of β1 activity is both a benefit (no arrhythmogenicity, no increased myocardial oxygen demand) and a limitation (no cardiac output augmentation in low-output states).1
Absorption, Distribution, Metabolism, and Excretion (ADME). Phenylephrine is available for multiple routes of administration. The intravenous (IV) formulation used for vasopressor support has an extremely short duration of action (approximately 5 to 10 minutes per bolus) because phenylephrine undergoes rapid metabolism by monoamine oxidase (MAO) in peripheral tissues, though somewhat more slowly than the endogenous catecholamines (it lacks the catechol structure, so it is not a substrate for catechol-O-methyltransferase (COMT), and instead relies on MAO and sulfation for metabolism). The oral formulation (used as a nasal decongestant) has poor bioavailability due to extensive first-pass MAO metabolism in the gut wall, which is the basis for controversy over its efficacy as an oral decongestant. Topical preparations (nasal, ophthalmic) avoid first-pass metabolism and produce reliable local effects. The half-life after IV administration is approximately 2 to 3 hours with hepatic and intestinal clearance, but the hemodynamic effect duration after a bolus is much shorter because redistribution removes the drug from its effector sites rapidly.1
Vasopressor Applications. Phenylephrine is used as a vasopressor in specific clinical contexts where its pure α1 profile is advantageous. In spinal anesthesia-induced hypotension (a very common indication in obstetric anesthesia), phenylephrine is the vasopressor of choice because it raises maternal blood pressure without the tachycardia associated with ephedrine, and in obstetric use it maintains or improves umbilical artery pH compared with ephedrine, which raises fetal heart rate through indirect mechanisms. The current standard in obstetric anesthesia is a phenylephrine infusion titrated to maintain maternal systolic pressure, initiated prophylactically at the time of spinal injection. In anesthesia-induced systemic hypotension from volatile agent vasodilation with preserved cardiac function, phenylephrine boluses (50 to 100 mcg IV) rapidly restore systemic vascular resistance. Phenylephrine is also the preferred vasopressor during anesthesia in patients with hypertrophic cardiomyopathy with outflow obstruction (HOCM), where tachycardia and reduced afterload both worsen the dynamic obstruction and where β1-stimulating agents are contraindicated.12
Nasal Decongestant and Ophthalmic Uses. Topical intranasal phenylephrine constricts the nasal mucosal vasculature via α1 receptors, reducing nasal congestion and mucosal edema. The oral formulation (10 mg, available over the counter) has been the subject of significant regulatory attention: a 2023 US Food and Drug Administration (FDA) advisory committee unanimously concluded that oral phenylephrine at the marketed 10 mg dose is not effective as a nasal decongestant, citing bioavailability data showing that approximately 38% undergoes intestinal MAO metabolism before reaching the portal circulation, and that plasma concentrations after oral dosing are insufficient to produce nasal mucosal vasoconstriction.3 Topical and intranasal phenylephrine remain effective. Ophthalmic phenylephrine (2.5% or 10% drops) produces mydriasis via α1-mediated iris dilator contraction, used for ophthalmic examination and before procedures requiring a dilated pupil. It does not cause cycloplegia (paralysis of the ciliary muscle) because it does not block muscarinic receptors; mydriasis without cycloplegia is a distinguishing feature compared with anticholinergic mydriatics such as tropicamide.1
Phenylephrine raises blood pressure by increasing SVR without direct cardiac stimulation. The baroreceptor reflex responds with vagally mediated bradycardia. In patients with marginal cardiac output, the increase in afterload from α1 vasoconstriction plus the reduction in heart rate can reduce cardiac output. Phenylephrine should be used with caution in cardiogenic shock and avoided when low cardiac output is already a problem. In patients with normal ventricular function undergoing spinal or general anesthesia, these concerns are generally outweighed by its clean selectivity profile.
Clonidine and dexmedetomidine are α2-adrenergic agonists that reduce sympathetic outflow by activating presynaptic α2 autoreceptors in the locus coeruleus (LC) of the brainstem. Their clinical utility spans antihypertensive therapy, perioperative analgesia and sympatholysis, procedural sedation, and intensive care unit (ICU) sedation. They share a mechanism but differ substantially in receptor selectivity, pharmacokinetics, and clinical applications.
Mechanism of Antihypertensive Effect. Both clonidine and dexmedetomidine act primarily on α2A receptors in the locus coeruleus, the principal noradrenergic nucleus of the brainstem, to reduce neuronal firing and decrease sympathetic outflow to the cardiovascular system. The resulting fall in plasma norepinephrine (NE) concentration reduces heart rate, cardiac contractility, and arteriolar tone, lowering blood pressure through a centrally mediated mechanism. This is distinct from the mechanism of peripheral vasodilators or diuretics. Because sympathetic outflow is reduced rather than blocked at the receptor, the cardiovascular response to stress and exercise is attenuated but not abolished. Clonidine also acts at peripheral postsynaptic α2 receptors, but the central effect is pharmacologically dominant at clinical doses. The sedative effect of both drugs is mediated by the same locus coeruleus α2A mechanism: reduced LC firing decreases the noradrenergic arousal signal to the cortex, producing a state resembling natural sleep with preserved arousability, which is the basis for dexmedetomidine's use in ICU sedation.4
Clonidine: Absorption, Distribution, Metabolism, and Excretion (ADME) and Clinical Applications. Clonidine is an imidazoline derivative with an α2 to α1 selectivity ratio of approximately 200:1. It is available as an oral tablet, a transdermal patch (Catapres-TTS), and an epidural formulation. Oral bioavailability is approximately 75 to 95%; peak plasma concentration is achieved at 1 to 3 hours. The plasma half-life is 6 to 24 hours (average approximately 12 hours), allowing twice-daily dosing, with the transdermal patch providing once-weekly delivery after a 2 to 3 day lag to achieve steady state. Clonidine is eliminated approximately 50% unchanged by renal excretion and 50% by hepatic metabolism, with dose adjustment required in severe renal impairment. Clinical applications include hypertension (particularly when combined with a diuretic; useful in patients who cannot tolerate first-line agents), attention deficit hyperactivity disorder (ADHD) in children (Kapvay formulation), opioid and nicotine withdrawal (reduces sympathetic hyperactivity), pain management (epidural clonidine is approved for cancer pain refractory to opioids), and menopausal hot flashes. The antihypertensive effect of clonidine is lost during general anesthesia (sympathetic responses are blocked by anesthesia), so continuation of clonidine in the perioperative period is primarily for prevention of withdrawal rather than blood pressure management.45
Dexmedetomidine: ADME and Clinical Applications. Dexmedetomidine is the pharmacologically active dextrorotatory enantiomer of medetomidine, with an α2 to α1 selectivity ratio of approximately 1600:1, making it substantially more α2-selective than clonidine. It is formulated for IV infusion only (peripheral or central venous). Protein binding is 94%, predominantly to albumin and alpha-1-acid glycoprotein. The drug undergoes almost complete hepatic metabolism by cytochrome P450 (CYP) isoforms CYP2A6 (the CYP2A6 isoform) and CYP1A2 (the CYP1A2 isoform), with no active metabolites; the elimination half-life is approximately 2 hours, making it more titratable than clonidine. Major clinical applications: ICU sedation in mechanically ventilated adults (Precedex; approved for up to 24 hours, though use beyond this duration is common in practice), procedural sedation, pain management as part of multimodal opioid-sparing analgesia, and management of alcohol withdrawal. Dexmedetomidine provides cooperative sedation: patients are easily aroused to follow commands and return to sleep without distress when stimulation is removed, unlike benzodiazepines, which produce a less arousable sedation. This property reduces delirium and facilitates extubation readiness assessments in the ICU.56
Clonidine Withdrawal Syndrome. The most important clinical hazard of both drugs is the withdrawal syndrome that follows abrupt discontinuation after chronic use. With chronic α2 agonist therapy, compensatory upregulation of α2 receptors and postsynaptic adrenergic receptor hypersensitivity develop. When the agonist is abruptly removed, the suddenly uninhibited sympathetic system is no longer subject to the tonic brake provided by the α2 autoreceptor feedback mechanism, and the hypersensitive adrenergic receptors amplify the resulting NE release. The clinical syndrome develops 12 to 24 hours after the last dose and includes severe hypertension (occasionally hypertensive emergency), tachycardia, anxiety, tremor, diaphoresis, and headache. In patients with coronary artery disease (CAD), the catecholamine surge can precipitate myocardial infarction or unstable angina. Management is reintroduction of clonidine followed by gradual tapering over 1 to 2 weeks. Dexmedetomidine withdrawal manifests similarly after prolonged infusion in the ICU and may contribute to agitation on discontinuation; gradual dose reduction is preferred.45
Selectivity: α2:α1 ratio 1600:1. Provides cooperative, arousable sedation resembling natural sleep; patients follow commands without distress. Reduces delirium compared with benzodiazepines (MIDEX and PRODEX trials). Does not cause respiratory depression at standard doses (unlike opioids and benzodiazepines) — patients can remain intubated or spontaneously ventilating. Causes bradycardia and hypotension at higher doses or during bolus injection; initial loading doses should be given cautiously. Half-life ~2 hours; hepatic metabolism; no active metabolites.
Orthostatic hypotension (OH), defined as a sustained drop in systolic blood pressure of at least 20 mmHg or diastolic blood pressure of at least 10 mmHg within 3 minutes of standing, is a common and disabling manifestation of autonomic dysfunction, volume depletion, or drug side effects. Two pharmacological agents with distinct mechanisms are the primary pharmacological treatments: midodrine, a selective α1 agonist prodrug, and fludrocortisone, a potent synthetic mineralocorticoid.
Midodrine: Mechanism and Pharmacology. Midodrine is administered as an oral prodrug that is hydrolyzed in the liver and plasma to its active metabolite desglymidodrine (also called ST-1059), a selective α1 adrenergic agonist. Desglymidodrine activates α1 receptors on arteriolar and venous smooth muscle, increasing systemic vascular resistance (SVR) and reducing venous pooling in dependent veins. The increased venous return improves preload and cardiac output in the upright position, thereby raising standing blood pressure. Midodrine's α1 selectivity means it does not produce β1-mediated tachycardia or β2-mediated bronchodilation, and unlike epinephrine or norepinephrine it does not readily cross the blood-brain barrier (BBB), minimizing central nervous system (CNS) side effects. The prodrug itself is rapidly absorbed orally with a bioavailability of approximately 93%; desglymidodrine reaches peak plasma concentration at approximately 1 to 2 hours and has a plasma half-life of approximately 3 to 4 hours. The drug and its metabolite are excreted primarily by renal mechanisms, and dosing should be reduced in patients with renal impairment (creatinine clearance (CrCl) below 30 mL/min).7
Midodrine Clinical Use. Midodrine is approved by the US Food and Drug Administration (FDA) for symptomatic orthostatic hypotension and is the most widely used oral vasopressor for this indication. The standard dose is 2.5 to 10 mg three times daily, timed to anticipated periods of upright activity. Because midodrine raises supine as well as standing blood pressure, the last dose of the day must be taken at least 4 hours before bedtime to avoid supine hypertension during sleep. Patients should be instructed to sleep with the head of the bed elevated 30 to 45 degrees (which activates the renin-angiotensin-aldosterone system (RAAS) and reduces overnight natriuresis) and to avoid supine rest for 4 hours after each dose. Clinical indications include autonomic failure syndromes (pure autonomic failure (PAF), multiple system atrophy (MSA), Parkinson's disease with autonomic dysfunction), postural orthostatic tachycardia syndrome (POTS), and dialysis-associated hypotension. The primary adverse effects are pilomotor erection (goosebumps), scalp tingling or pruritus (from α1-mediated piloerector and cutaneous vascular activation), urinary urgency and retention (α1 contraction of internal urethral sphincter), and supine hypertension. Midodrine is contraindicated in patients with severe organic heart disease, urinary retention, thyrotoxicosis, and pheochromocytoma.7
Fludrocortisone: Mechanism and Role in Orthostatic Hypotension. Fludrocortisone is a synthetic corticosteroid with potent mineralocorticoid and weak glucocorticoid activity. It binds the mineralocorticoid receptor (MR) in the renal collecting duct principal cells, promoting transcription of sodium-potassium-adenosine triphosphatase (Na-K-ATPase) and the epithelial sodium channel (ENaC), increasing renal sodium and water reabsorption and expanding intravascular volume. The expanded plasma volume improves cardiac preload and orthostatic tolerance, though the mechanism also involves enhancement of peripheral vascular responsiveness to catecholamines through upregulation of α1 receptor expression and sensitivity. The usual dose is 0.05 to 0.2 mg per day orally. Adverse effects include supine hypertension, hypokalemia (requires monitoring and often supplementation), and peripheral edema. Because fludrocortisone acts primarily through volume expansion, it works best in patients with autonomic failure who have intact renal function and the ability to retain sodium, and it is less effective when the renin-angiotensin system is already maximally activated (as in severe heart failure). Fludrocortisone and midodrine are complementary and are frequently used together in patients with severe orthostatic hypotension.78
Dose: 2.5–10 mg three times daily. Take 30 minutes before anticipated upright activity. Do NOT take within 4 hours of bedtime — supine hypertension during sleep. Elevate head of bed 30–45 degrees at night. Last dose no later than mid-afternoon if bedtime is around 10 pm. Monitor supine blood pressure regularly. Hold dose if supine systolic blood pressure exceeds 180 mmHg.
The beta-2 selective bronchodilators represent one of the most clinically important applications of receptor selectivity engineering in pharmacology. By designing agents with high β2 to β1 selectivity ratios and by delivering them by inhalation, pharmaceutical development reduced the systemic cardiovascular effects of bronchodilator therapy while maintaining efficacy at the airway level. Understanding the pharmacological basis for this selectivity, and the differences between short-acting and long-acting agents, is essential for rational prescribing in asthma and chronic obstructive pulmonary disease (COPD).
Basis of Beta-2 Selectivity. All beta-2 selective agonists share structural modifications to the catecholamine scaffold that increase their affinity for β2 receptors relative to β1 receptors. These modifications primarily involve substitutions at the N-alkyl side chain (larger groups increase β2 selectivity) and changes to the catechol ring (substitutions at the 3 and 4 positions that alter receptor binding geometry). Despite these structural modifications, β2 selectivity is relative and not absolute; at high doses or systemic concentrations, all beta-2 selective agonists produce β1-mediated cardiac effects including tachycardia, increased contractility, and potential arrhythmias. The inhaled route of administration significantly reduces systemic exposure by limiting the absorbed dose, making pharmacokinetics a key determinant of the safety profile of these agents. Additionally, the β2 receptor proportion in the heart increases in heart failure (as discussed in Module 1), meaning that patients with heart failure have greater cardiac sensitivity to β2-selective agonists than do patients with normal cardiac function.9
Albuterol (Salbutamol): Short-Acting Beta-2 Agonist. Albuterol (known internationally as salbutamol) is the prototype short-acting beta-2 agonist (SABA) and the most widely prescribed bronchodilator worldwide. It is a racemic mixture of R- and S-albuterol enantiomers; the R-enantiomer is the pharmacologically active bronchodilator and is available as the pure enantiomer levalbuterol. Albuterol produces bronchodilation by activating β2 receptors in airway smooth muscle, activating protein kinase A (PKA), inhibiting myosin light-chain kinase (MLCK), and opening large-conductance calcium-activated potassium (BK) channels, resulting in smooth muscle relaxation. The onset of bronchodilation after inhalation is 5 to 15 minutes; peak effect is at 30 to 60 minutes; duration is 4 to 6 hours. Oral albuterol is available but has significantly greater systemic exposure and cardiovascular adverse effects than the inhaled form and is rarely used. Systemic adverse effects of albuterol at therapeutic inhaled doses include tremor (β2-mediated skeletal muscle tremor from Na-K-ATPase activation), tachycardia, and hypokalemia (intracellular potassium shift via Na-K-ATPase activation). In the setting of acute severe asthma requiring high-dose nebulized albuterol, clinically significant hypokalemia and tachycardia are common and should be monitored and treated.910
Long-Acting Beta-2 Agonists: Salmeterol and Formoterol. Long-acting beta-2 agonists (LABAs) provide sustained bronchodilation for 12 hours (salmeterol, formoterol) or 24 hours (indacaterol, vilanterol) per dose, compared with 4 to 6 hours for SABAs. The pharmacokinetic basis for prolonged duration differs between the two main LABAs. Salmeterol achieves prolonged action through its long lipophilic sidechain, which anchors it to the lipid bilayer near the β2 receptor, allowing the active head group to repeatedly bind and dissociate from the receptor (the "jackknife" model of sustained activation). Salmeterol has a slow onset of action (15 to 20 minutes to significant bronchodilation) and cannot be used for acute rescue. Formoterol, by contrast, has a rapid onset (1 to 3 minutes) despite 12-hour duration because it binds directly to the receptor without the membrane-anchoring mechanism; it can therefore be used for both maintenance and rescue dosing in some clinical protocols. Both salmeterol and formoterol are used exclusively as inhaled agents (MDI (metered-dose inhaler) or DPI (dry powder inhaler) formulations) and should only be prescribed in combination with inhaled corticosteroids (ICS) for persistent asthma, never as monotherapy.10
Long-Acting Beta-2 Agonist (LABA) Safety, ICS Co-administration Requirement, and the Salmeterol Safety Trial. The Salmeterol Multicenter Asthma Research Trial (SMART, 2006) found a small but statistically significant increase in asthma-related deaths and life-threatening exacerbations in patients randomized to salmeterol versus placebo, particularly in African American patients. The mechanism is debated but likely involves the sustained β2 receptor downregulation produced by chronic LABA use without adequate airway anti-inflammatory therapy, which may increase airway hyperresponsiveness during periods of exacerbation when the LABA cannot overcome worsening bronchoconstriction. Based on this and subsequent data, regulatory agencies (FDA, MHRA) now mandate that LABAs be co-prescribed only with ICS, never as LABA monotherapy, for asthma. In COPD, where anti-inflammatory treatment with ICS has less-established benefit, LABA monotherapy is approved and widely used; the safety concern is specific to asthma. Fixed-dose inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination inhalers (fluticasone/salmeterol, budesonide/formoterol, and others) are the standard of care for persistent asthma requiring maintenance therapy.1011
Albuterol (SABA): Onset 5–15 min; duration 4–6 hrs. Rescue bronchodilator for acute symptoms. Regular use >2 times/week for symptoms indicates inadequate asthma control — requires addition of controller therapy. Monitor for tachycardia and hypokalemia with high-dose nebulized use. Salmeterol (LABA): Onset 15–20 min (no rescue use); duration 12 hrs. Use only with ICS in asthma. Formoterol (LABA): Rapid onset (1–3 min) + 12-hr duration; may serve maintenance and rescue in some protocols (SMART therapy). Only with ICS in asthma. Never prescribe LABA without ICS in asthma.
Isoproterenol and terbutaline occupy defined but narrow clinical niches in contemporary practice. Isoproterenol is a non-selective beta agonist primarily used for its cardiac electrophysiological effects. Terbutaline shares the beta-2 agonist bronchodilatory mechanism with albuterol but is distinguished by its important, and now tightly regulated, use as a uterine relaxant (tocolytic) for management of acute preterm labor.
Isoproterenol: Mechanism and Clinical Uses. Isoproterenol is a synthetic catecholamine that is a potent, non-selective full agonist at β1 and β2 receptors with essentially no α-adrenergic activity at any dose. At β1 receptors in the heart, it produces the full range of positive chronotropic, inotropic, and dromotropic effects. At β2 receptors in the peripheral vasculature, it causes vasodilation, reducing systemic vascular resistance (SVR) and diastolic blood pressure. The combined effect of increased cardiac output and decreased SVR is a rise in pulse pressure with systolic pressure increasing and diastolic pressure falling; mean arterial pressure (MAP) is often unchanged or slightly reduced because the vasodilation offsets the cardiac stimulation. This hemodynamic profile distinguishes isoproterenol from norepinephrine (which increases both systolic and diastolic pressure) and from dobutamine (which is β1-dominant with partial β2 vasodilation). Because of its profound chronotropic and arrhythmogenic effects, isoproterenol has been largely replaced by more targeted agents in most indications, but retains defined roles in clinical electrophysiology and specific bradyarrhythmia settings.12
Current Clinical Applications of Isoproterenol. In contemporary practice, isoproterenol is used in several specific clinical contexts. In patients with symptomatic bradycardia caused by high-degree atrioventricular (AV) block (second-degree or complete heart block) as a temporary bridge to transvenous pacing, isoproterenol increases ventricular escape rate through β1-mediated enhancement of automaticity in ventricular conduction tissue. In cardiac electrophysiology (EP) laboratories, isoproterenol infusion is used to induce supraventricular and ventricular arrhythmias for diagnostic evaluation and catheter ablation mapping, exploiting its ability to increase automaticity and shorten refractory periods. It is also used to test arrhythmia inducibility after catheter ablation and in Brugada syndrome unmasking (though the latter is more controversial). In patients with ventricular tachycardia (VT) storm associated with long QT (QT interval prolongation on electrocardiography) syndrome or torsades de pointes (TdP), isoproterenol infusion increases heart rate, shortening the QT interval and suppressing pause-dependent arrhythmias. Isoproterenol should not be used in cardiogenic shock (it will worsen the mismatch between myocardial oxygen supply and demand), in obstructive cardiomyopathy, or in patients with known severe coronary artery disease outside of life-threatening arrhythmia contexts.12
Terbutaline: Pharmacology and Tocolytic Mechanism. Terbutaline is a synthetic β2-selective adrenergic agonist structurally related to albuterol, used in respiratory medicine as a bronchodilator and in obstetrics as a uterine relaxant. In the uterus, β2 receptor activation by terbutaline stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP) and activating protein kinase A (PKA). PKA phosphorylates and inactivates myosin light-chain kinase (MLCK), preventing actin-myosin cross-bridge formation in uterine smooth muscle and producing uterine relaxation (tocolysis). Terbutaline is available for subcutaneous injection and oral administration; the IV route is used in some protocols for acute tocolysis. Onset of uterine relaxation after subcutaneous injection is approximately 5 to 15 minutes. Maternal adverse effects of terbutaline are mediated by its β2 and residual β1 activity: palpitations, tachycardia, tremor, hypokalemia, hyperglycemia, and anxiety are common. Because terbutaline does not cross the placenta in clinically significant amounts at standard doses, fetal effects are mainly limited to fetal tachycardia from the maternal cardiovascular response rather than direct fetal β2 stimulation.13
FDA Black Box Warning and Current Tocolytic Practice. The FDA issued a black box warning in 2011 prohibiting the use of injectable terbutaline for prolonged tocolysis (beyond 48 to 72 hours) and the use of oral terbutaline for tocolysis entirely. This followed reports of serious maternal cardiovascular adverse events including maternal deaths from cardiac arrhythmias and pulmonary edema associated with extended terbutaline infusions. Terbutaline retains a narrow approved role: acute, short-term (up to 48 to 72 hours) tocolysis to allow fetal lung maturation with corticosteroids when preterm labor occurs between 24 and 34 weeks gestation. It should not be used in women with cardiac disease, poorly controlled diabetes mellitus, thyrotoxicosis, or placenta previa. The only tocolytic agent currently FDA-approved specifically for this indication is nifedipine and, in some guidelines, indomethacin; however, terbutaline and ritodrine (a related β2 agonist now largely withdrawn) have extensive historical use and terbutaline remains in use off-label for acute short-term tocolysis in clinical practice.1314
Injectable terbutaline is NOT approved for prolonged tocolysis (beyond 48–72 hours). Oral terbutaline is NOT approved for tocolysis at any duration. Risk: serious maternal cardiac arrhythmias, pulmonary edema, and death associated with prolonged infusion. Acceptable use: subcutaneous terbutaline for acute short-term tocolysis to allow corticosteroid administration for fetal lung maturation between 24 and 34 weeks gestation, with hemodynamic monitoring. Contraindications: cardiac disease, poorly controlled diabetes, thyrotoxicosis, placenta previa. Maximum acceptable duration: 48–72 hours.
The synthetic adrenergic agonists interact with several major drug classes through mechanisms that either augment their effects to dangerous levels, block their intended actions, or produce additive toxicity. Most interactions are extensions of the receptor pharmacology covered in Module 02; this section focuses on the interactions specific to or clinically most relevant for the synthetic agonist class.
Beta-Blockers and Beta-2 Agonists. Non-selective beta-blockers (propranolol, nadolol, timolol, carvedilol) block β2 receptors in the airway, opposing the bronchodilatory effect of albuterol, salmeterol, and terbutaline. In patients with asthma or reactive airway disease receiving non-selective beta-blockade, beta-2 agonist bronchodilators may be partially or completely ineffective, creating a potentially life-threatening situation during acute bronchospasm. This interaction mandates either avoidance of non-selective beta-blockers in patients with asthma (using cardioselective agents such as metoprolol or atenolol instead, which have significantly less β2 blockade at standard doses) or accepting that high doses of nebulized albuterol may be required to overcome partial β2 blockade. In severe anaphylaxis in patients on non-selective beta-blockers, neither the β2-mediated bronchodilation nor the β2-mediated mast cell mediator suppression from epinephrine is effective, and glucagon must be added as previously described in Module 02. Selective beta-1 blockers at standard doses have minimal effect on beta-2 agonist bronchodilation, though selectivity is dose-dependent and high-dose metoprolol can produce clinically significant β2 blockade in susceptible patients.15
Monoamine Oxidase (MAO) Inhibitors and Alpha-2 Agonists. Clonidine and monoamine oxidase inhibitors (MAOIs; each individual drug abbreviated as MAOI) have a complex interaction. MAOIs prevent the breakdown of norepinephrine and other catecholamines; when a patient on an MAOI takes clonidine, the initial response may include a transient paradoxical hypertensive effect mediated by peripheral postsynaptic α2 receptor activation on vascular smooth muscle (which normally contributes to vasoconstriction) before the central sympatholytic effect becomes dominant. Of greater clinical concern, when clonidine is used in a patient on an MAOI and is then discontinued, the rebound norepinephrine (NE) release from clonidine withdrawal falls on receptors that cannot catabolize the excess NE, dramatically amplifying the rebound hypertensive response. The combination requires extreme caution and should generally be avoided. MAO inhibitors also interact with midodrine's active metabolite desglymidodrine: inhibition of MAO reduces the metabolism of desglymidodrine, increasing its plasma concentration and vasopressor effect, with risk of severe hypertension.47
Isoproterenol and QT (QT Interval)-Prolonging Agents. Isoproterenol is used therapeutically to shorten the QT interval in torsades de pointes (TdP) and long QT syndrome, and is therefore beneficial rather than harmful in that specific context. However, when isoproterenol is used in other clinical contexts (pacing support, EP testing), co-administration of drugs that prolong the QT interval (antiarrhythmics of Class IA (quinidine, procainamide) and Class III (amiodarone, sotalol), antipsychotics, certain antibiotics such as fluoroquinolones and azithromycin, and antihistamines such as terfenadine) creates a risk of arrhythmias driven by the combined effects of increased heart rate (which can be arrhythmogenic in patients with abnormal repolarization) and QT prolongation. The combination should be used only when the indication is compelling and with continuous cardiac monitoring.12
Terbutaline and Corticosteroids: Hypokalemia Synergy. Beta-2 agonists lower serum potassium by activating the Na-K-ATPase pump in skeletal muscle, shifting potassium intracellularly. Systemic corticosteroids (prednisone, methylprednisolone), frequently co-administered in the management of acute asthma exacerbations, produce hypokalemia through their mineralocorticoid activity, promoting renal potassium excretion via ENaC upregulation. When high-dose nebulized or systemic beta-2 agonists are combined with systemic corticosteroids in the management of severe acute asthma, the hypokalemic effect is additive and can produce clinically significant hypokalemia (serum potassium below 3.0 mEq/L), which increases the risk of cardiac arrhythmias, particularly in patients with pre-existing cardiac disease. Serum potassium should be monitored during treatment of severe acute asthma with high-dose beta-2 agonists and systemic steroids, and replacement provided as needed.910
Non-selective beta-blockers + beta-2 agonists: β2 blockade opposes bronchodilation; use cardioselective agents (metoprolol, atenolol) in patients requiring beta-blockade with reactive airways; add glucagon in anaphylaxis if beta-blocker cannot be reversed. MAOIs + clonidine: avoid; withdrawal rebound amplified by MAOI-blocked NE catabolism. MAOIs + midodrine: increased desglymidodrine concentration; hypertension risk. Isoproterenol + QT-prolonging drugs: use only for TdP/long QT indication with monitoring. Beta-2 agonists + corticosteroids: additive hypokalemia in acute asthma management; monitor potassium during high-dose nebulized therapy. LABAs without ICS in asthma: increased asthma-related death risk (SMART trial); mandatory co-prescription of ICS.
Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: Brunton LL, Chabner BA, Knollmann BC, eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. 13th ed. McGraw-Hill; 2018:191-224.
Heesen M, Kolhr S, Rossaint R, Straube S. Prophylactic phenylephrine for caesarean section under spinal anaesthesia: systematic review and meta-analysis. Anaesthesia. 2014;69(2):143-165.
doi:10.1111/anae.12445Kollar C, Schneider H, Waksman J, Krusinska E. Meta-analysis of the efficacy of a single oral dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. Clin Ther. 2007;29(6):1057-1070.
doi:10.1016/j.clinthera.2007.05.021Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology. 2000;93(5):1345-1349.
doi:10.1097/00000542-200011000-00030Giovannitti JA Jr, Thoms SM, Crawford JJ. Alpha-2 adrenergic receptor agonists: a review of current clinical applications. Anesth Prog. 2015;62(1):31-39.
doi:10.2344/0003-3006-62.1.31Pandharipande PP, Patel MB, Barr J. Management of pain, agitation, and delirium in critically ill patients. Pol Arch Med Wewn. 2014;124(3):114-123.
doi:10.20452/pamw.2136Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension: a randomized, double-blind multicenter study. JAMA. 1997;277(13):1046-1051.
doi:10.1001/jama.1997.03540370036033Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006;13(9):930-936.
doi:10.1111/j.1468-1331.2006.01512.xJohnson M. Molecular mechanisms of beta2-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol. 2006;117(1):18-24.
doi:10.1016/j.jaci.2005.11.012Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Updated 2024. Available at: https://ginasthma.org
Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15-26.
doi:10.1378/chest.129.1.15Zimetbaum P. Antiarrhythmic drug therapy for atrial fibrillation. Circulation. 2012;125(2):381-389.
doi:10.1161/CIRCULATIONAHA.111.019927Gyetvai K, Hannah ME, Hodnett ED, Ohlsson A. Tocolytics for preterm labor: a systematic review. Obstet Gynecol. 1999;94(5 Pt 2):869-877.
doi:10.1016/S0029-7844(99)00329-4American College of Obstetricians and Gynecologists. Practice Bulletin No. 171: Management of preterm labor. Obstet Gynecol. 2016;128(4):e155-e164.
doi:10.1097/AOG.0000000000001711Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.
doi:10.1002/14651858.CD003566.pub2